Compare Baxter International Inc (BAX) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Enovix Corporation — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Enovix Corporation trades at $5.09 (market cap $1.10B). The key difference: Baxter International Inc is far larger — about 10.2× Enovix Corporation's market cap, and Baxter International Inc pays a 0.92% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| BAX | ENVX | |
|---|---|---|
Market Cap | $11.26B | $1.10B |
Sector | Health | Technology |
52-Week High | $29.22 | $15.93 |
52-Week Low | $15.80 | $4.84 |
Enterprise Value | $18.93B | $1.12B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
ENVX trades at $4.95, down 4.81% with bearish technical signals despite recent earnings beats. The company shows negative profitability with -499.64% net margin and -$156.74M net loss for 2025, though revenue grew to $31.82M. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in battery technology commercialization.
While analyst consensus remains bullish with a $12.75 price target, significant execution risks persist given negative cash flows and high valuation multiples. The stock presents high-risk speculation on Enovix's ability to scale production and achieve profitability in the competitive battery technology market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
